Track GALT and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Galectin Therapeutics Inc
4960 Peachtree Industrial Boulevard, Norcross, GA, United States, 30071
IPO
2002
Employees
9
Industry
Biotechnology
Sector
Healthcare
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q1 20269-8
1
Q4 20259-8
1
2-quarter cumulative
18 sells2 buys
Analyst Ratings
No coverage data
No analyst ratings data available